Health & Fitness
Health and Fitness
Health and Fitness 
Thu, February 5, 2009
Wed, February 4, 2009
Inhibitex to Present at the 11th Annual BIO CEO & Investor Conference
ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (Nasdaq: INHX) announced today that it will present at the BIO CEO & Investor Conference on Tuesday, February 10, 2009 at 1:45 p.m. EST from the Waldorf=Astoria Hotel in New York, NY. Russell H. Plumb, president and chief executive officer of Inhibitex, Inc., and Joseph M. Patti, Ph.D., senior vice president of research and development and chief scientific officer, will provide an update on the Company.
A live audio webcast of the presentation will be available in the "News and Events" section of the Company's website at [ www.inhibitex.com ]. The webcast will be archived and available on the Inhibitex website after the event for a period of 30 days.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases. The Company's pipeline includes FV-100, its clinical-stage oral nucleoside analogue in development for the treatment of herpes zoster (shingles), as well as a series of HCV nucleoside polymerase inhibitors and HIV integrase inhibitors. Inhibitex has also licensed certain of its proprietary MSCRAMM® protein technology to Wyeth for the development of staphylococcal vaccines and to 3M for the development of diagnostics.
For additional information about the Company, please visit [ www.inhibitex.com ].
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.